Literature DB >> 12609569

The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up.

Roy M Bremnes1, Stein Sundstrom, Ulf Aasebø, Stein Kaasa, Reidulv Hatlevoll, Steinar Aamdal.   

Abstract

We have evaluated the prognostic value of 22 pretreatment attributes in 436 small cell lung cancer (SCLC) patients included in a prospective multicenter study with a minimum 5-year follow-up. Pretreatment clinical and laboratory parameters were registered. Possible prognostic factors were evaluated by univariate analysis (log rank test) and by the Cox multivariate regression model. In the univariate analysis of all patients, only age, nodal metastasis, and skin metastasis were not associated with survival. The multivariate Cox model identified gender, extent of disease, performance status (PS), weight loss, platelet count, LDH, and NSE as independent prognostic factors. In subset multivariate analyses according to extent of disease, we found haemoglobin level, PS, NSE, and total WBC as significant prognostic indicators for survival in limited-stage disease (LD-SCLC), while PS, weight loss, LDH, number of metastases, liver metastases, and brain metastases were identified as independent prognostic factors in extensive-stage disease (ED-SCLC). There was a significant correlation between serum LDH and NSE levels. In conclusion, gender, extent of disease, PS, weight loss, haemoglobin, WBC count, platelet count, LDH, and NSE were all found to be independent prognostic factors for SCLC survival. However, the prognostic value of these factors depends highly on whether all or subsets of SCLC patients are studied.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12609569     DOI: 10.1016/s0169-5002(02)00508-1

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  55 in total

Review 1.  Small cell lung cancer: past, present, and future.

Authors:  Estelamari Rodriguez; Rogerio C Lilenbaum
Journal:  Curr Oncol Rep       Date:  2010-09       Impact factor: 5.075

2.  CK-19 mRNA-positive cells in peripheral blood predict treatment efficacy and survival in small-cell lung cancer patients.

Authors:  Wei-Lin Shi; Jian Li; Yong-Jie Du; Wen-Fang Zhu; Yan Wu; Yi-Ming Hu; Yong-Chang Chen
Journal:  Med Oncol       Date:  2013-11-01       Impact factor: 3.064

3.  Prognostic and predictive value of plasma D-dimer levels in patients with small-cell lung cancer.

Authors:  Cuicui Zhang; Yongsheng Jia; Yanan Jia; Xiaoling Zhang; Kai Li
Journal:  Int J Clin Oncol       Date:  2018-08-27       Impact factor: 3.402

4.  miR-126/VCAM-1 regulation by naringin suppresses cell growth of human non-small cell lung cancer.

Authors:  Mingjiu Chen; Weilin Peng; Shifeng Hu; Jie Deng
Journal:  Oncol Lett       Date:  2018-07-24       Impact factor: 2.967

5.  Lysosome-associated protein transmembrane-4β-35 is a novel independent prognostic factor in small cell lung cancer.

Authors:  Man Qiao; Guohua Hu
Journal:  Tumour Biol       Date:  2015-04-25

6.  The prognostic factors in the elderly patients with small cell lung cancer: a retrospective analysis from a single cancer institute.

Authors:  Sujing Liu; Hongbo Guo; Li Kong; Huihui Li; Yan Zhang; Hui Zhu; Jinming Yu
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

7.  Estrogen Plus Progestin and Lung Cancer: Follow-up of the Women's Health Initiative Randomized Trial.

Authors:  Rowan T Chlebowski; Heather Wakelee; Mary Pettinger; Thomas Rohan; Jingmin Liu; Michael Simon; Hilary Tindle; Catherine Messina; Karen Johnson; Ann Schwartz; Margery Gass; Jean Wactawski-Wende
Journal:  Clin Lung Cancer       Date:  2015-10-22       Impact factor: 4.785

8.  Survival and prognostic factors in small cell lung cancer.

Authors:  Jian Li; Chun-Hua Dai; Ping Chen; Jian-Nong Wu; Quan-Lei Bao; Hao Qiu; Xiao-Qin Li
Journal:  Med Oncol       Date:  2009-02-12       Impact factor: 3.064

9.  Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy.

Authors:  Jian-Mei Hou; Alastair Greystoke; Lee Lancashire; Jeff Cummings; Tim Ward; Ruth Board; Eitan Amir; Sarah Hughes; Matthew Krebs; Andrew Hughes; Malcolm Ranson; Paul Lorigan; Caroline Dive; Fiona H Blackhall
Journal:  Am J Pathol       Date:  2009-07-23       Impact factor: 4.307

10.  Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial.

Authors:  Rowan T Chlebowski; Ann G Schwartz; Heather Wakelee; Garnet L Anderson; Marcia L Stefanick; JoAnn E Manson; Rebecca J Rodabough; Jason W Chien; Jean Wactawski-Wende; Margery Gass; Jane Morley Kotchen; Karen C Johnson; Mary Jo O'Sullivan; Judith K Ockene; Chu Chen; F Allan Hubbell
Journal:  Lancet       Date:  2009-09-18       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.